Stephanie A. Leonard
A5103223248- Food Allergy and Anaphylaxis Research
- Allergic Rhinitis and Sensitization
- Eosinophilic Esophagitis
- Contact Dermatitis and Allergies
- Respiratory and Cough-Related Research
- Polyomavirus and related diseases
- Food Safety and Hygiene
- Asthma and respiratory diseases
- Pediatric health and respiratory diseases
- Child Nutrition and Feeding Issues
- Viral gastroenteritis research and epidemiology
- Celiac Disease Research and Management
- Respiratory viral infections research
- Transgenic Plants and Applications
- Dermatology and Skin Diseases
- Infant Nutrition and Health
- Animal and Plant Science Education
- Insect behavior and control techniques
- Folate and B Vitamins Research
- Influenza Virus Research Studies
- Insect and Arachnid Ecology and Behavior
- Breastfeeding Practices and Influences
- Insect Utilization and Effects
- Porphyrin Metabolism and Disorders
- Immune Response and Inflammation
University of California, San Diego
2016-2025
University of Cambridge
2025
Rady Children's Hospital-San Diego
2015-2024
National Center on Birth Defects and Developmental Disabilities
2018
University of Iowa
2018
Triangle
2018
John Wiley & Sons (United States)
2018
Boston Children's Hospital
2013
Icahn School of Medicine at Mount Sinai
2011-2012
Mount Sinai Hospital
2009-2011
Food protein–induced enterocolitis (FPIES) is a non-IgE cell- mediated food allergy that can be severe and lead to shock. Despite the potential seriousness of reactions, awareness FPIES low; high-quality studies providing insight into pathophysiology, diagnosis, management are lacking; clinical outcomes poorly established. This consensus document result work done by an international workgroup convened through Adverse Reactions Foods Committee American Academy Allergy, Asthma & Immunology...
There are currently no approved treatments for peanut allergy.To assess the efficacy and adverse events of epicutaneous immunotherapy with a patch among peanut-allergic children.Phase 3, randomized, double-blind, placebo-controlled trial conducted at 31 sites in 5 countries between January 8, 2016, August 18, 2017. Participants included children (aged 4-11 years [n = 356] without history severe anaphylactic reaction) developing objective symptoms during food challenge an eliciting dose 300...
<h3>Importance</h3> Epicutaneous immunotherapy may have potential for treating peanut allergy but has been assessed only in preclinical and early human trials. <h3>Objective</h3> To determine the optimal dose, adverse events (AEs), efficacy of a patch treatment. <h3>Design, Setting, Participants</h3> Phase 2b double-blind, placebo-controlled, dose-ranging trial peanut-allergic patients (6-55 years) from 22 centers, with 2-year, open-label extension (July 31, 2012-July 2014; completed...
Peanut oral immunotherapy, using a variety of approaches, has been previously shown to induce desensitization in peanut-allergic subjects, but no products have approved for clinical use by regulatory agencies.We performed the first phase 2 multicentered study assess safety and efficacy AR101, novel biologic drug product.A randomized, double-blind, placebo-controlled trial was conducted at 8 US centers. Eligible subjects were 4 26 years old, sensitized peanut, had dose-limiting symptoms ≤143...
No approved treatment for peanut allergy exists children younger than 4 years of age, and the efficacy safety epicutaneous immunotherapy with a patch in toddlers are unknown. We conducted this phase 3, multicenter, double-blind, randomized, placebo-controlled trial involving 1 to 3 age confirmed by food challenge. Patients who had an eliciting dose (the necessary elicit allergic reaction) 300 mg or less protein were assigned 2:1 ratio receive delivered means (intervention group) placebo...
The PEPITES (Peanut EPIT Efficacy and Safety) trial, a 12-month randomized controlled study of children with peanut allergy 4 to 11 years old, previously reported the safety efficacy epicutaneous immunotherapy (EPIT) for (250 μg, daily protein; DBV712 250 μg).We sought assess interim an additional 2 from ongoing (5-year treatment) PEOPLE (PEPITES Open-Label Extension) study.Subjects who completed were offered enrollment in PEOPLE. Following subjects had received μg underwent month-36...
The randomized, controlled PALISADE trial demonstrated the benefit of daily oral immunotherapy with Peanut (Arachis Hypogaea) allergen powder-dnfp (PTAH, formerly AR101) in peanut-allergic children and adolescents.ARC004, open-label follow-on study to PALISADE, used 5 dosing cohorts explore PTAH treatment beyond 1 year alternative regimens individuals.Active arm (PTAH-continuing) participants who tolerated 300-mg peanut protein at exit double-blind placebo-controlled food challenge placebo...
No approved treatment exists for allergen-specific immunoglobulin E (IgE)-mediated cow's milk allergy (CMA), a common childhood food allergy.
Abstract The black soldier fly ( Hermetia illucens L., Diptera: Stratiomyidae) has emerged as a key species in the sustainable protein industry. Whilst genetic variation performance been suggested, extent of heritability and genotype‐by‐environment (G × E) interactions this remains relatively unexplored. This study used standardised split‐brood design linear mixed effect models to evaluate effects at between‐ within‐strain levels across diets environments. In first experiment, three strains...
Cow's milk and hen's egg are ubiquitous in diets around the world can be important sources of protein young children. Unfortunately, allergies also some most common food childhood. Less allergenic forms due to heating interactions with a matrix, as baked goods, tolerated by majority milk- egg-allergic patients. Adding into children broaden diets, increase nutrition, improve quality life. Most important, regular ingestion help outgrow their egg. This article will review our current...
Polygenic traits are expected to show high genetic redundancy and therefore low repeatability in the genomic response selection. We tested this prediction by selecting for large body size black soldier fly (Hermetia illucens). Over three replicate experiments selected size, we found a strong repeatable phenotypic response, with mean 15% increase size. Selected lines also increased larval growth rate (+19%) average protein content (+14%), suggesting that selection on does not result...